KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EPS (Basic) (2016 - 2025)

Jazz Pharmaceuticals has reported EPS (Basic) over the past 16 years, most recently at $3.34 for Q4 2025.

  • Quarterly EPS (Basic) rose 6.71% to $3.34 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.26 through Dec 2025, down 146.92% year-over-year, with the annual reading at -$5.84 for FY2025, 164.46% down from the prior year.
  • EPS (Basic) was $3.34 for Q4 2025 at Jazz Pharmaceuticals, down from $4.14 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $4.14 in Q3 2025 and troughed at -$11.74 in Q2 2025.
  • The 5-year median for EPS (Basic) is $1.09 (2023), against an average of $0.13.
  • Biggest five-year swings in EPS (Basic): tumbled 612.96% in 2022 and later surged 3533.33% in 2023.
  • Tracing JAZZ's EPS (Basic) over 5 years: stood at -$0.54 in 2021, then tumbled by 612.96% to -$3.85 in 2022, then soared by 138.96% to $1.5 in 2023, then surged by 108.67% to $3.13 in 2024, then grew by 6.71% to $3.34 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at $3.34, $4.14, and -$11.74 for Q4 2025, Q3 2025, and Q2 2025 respectively.